Norvir “March In” Would Deter Future NIH/Industry Collaboration, Bayh Warns
Executive Summary
Abbott has the support of one of the authors of the federal technology transfer laws in its fight to prevent the National Institutes of Health from "marching in" on its Norvir patents
You may also be interested in...
Norvir Generics Are Years Away, Even If NIH Exercises “March-In” Rights
Generic versions of Abbott's protease inhibitor Norvir (ritonavir) would still face patent litigation, even if the National Institutes of Health decides to "march in" on the patents for the drug
Norvir Generics Are Years Away, Even If NIH Exercises “March-In” Rights
Generic versions of Abbott's protease inhibitor Norvir (ritonavir) would still face patent litigation, even if the National Institutes of Health decides to "march in" on the patents for the drug
Abbott Norvir Compulsory Licensing Will Be Debated By NIH
An NIH public hearing on Abbott's Norvir will address whether the federal government should use "march-in" authorities to grant compulsory licensing of Norvir patents